Institutional shares held 84.5 Million
2.06M calls
1.52M puts
Total value of holdings $8.84B
$216M calls
$159M puts
Market Cap $9.34B
87,567,904 Shares Out.
Institutional ownership 96.47%
# of Institutions 531


Latest Institutional Activity in SRPT

Top Purchases

Q3 2024
Capital International Investors Shares Held: 6.26M ($667M)
Q3 2024
Groupama Asset Managment Shares Held: 1.3M ($139M)
Q3 2024
Wellington Management Group LLP Shares Held: 2.73M ($291M)
Q3 2024
Erste Asset Management Gmb H Shares Held: 636K ($67.8M)
Q3 2024
Camber Capital Management LP Shares Held: 775K ($82.6M)

Top Sells

Q3 2024
Morgan Stanley Shares Held: 953K ($102M)
Q3 2024
Jane Street Group, LLC Shares Held: 44K ($4.69M)
Q3 2024
Millennium Management LLC Shares Held: 22.1K ($2.35M)
Q3 2024
Two Sigma Advisers, LP Shares Held: 128K ($13.7M)
Q3 2024
Avoro Capital Advisors LLC Shares Held: 2.56M ($272M)

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at SRPT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
162K Shares
From 20 Insiders
Grant, award, or other acquisition 39.8K shares
Exercise of conversion of derivative security 84.8K shares
Open market or private purchase 37K shares
Sell / Disposition
118K Shares
From 13 Insiders
Open market or private sale 84.4K shares
Bona fide gift 746 shares
Payment of exercise price or tax liability 32.5K shares

Track Institutional and Insider Activities on SRPT

Follow Sarepta Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT